We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesWerewolf Therapeutics Inc

Werewolf Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.9962 USD 0.01 ( 0.74%)
Last update at 2026-11-12T15:40:00Z
VOLUME
25164
Market Cap
47.63M

Momentum Score

…

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.98
Low
1.00
High
52 Week Price Range
0.27
Low
2.38
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Werewolf Therapeutics Inc is a clinical-stage biotech developing tumor-activated cytokines intended to concentrate immune stimulation in the tumor microenvironment while limiting systemic exposure. Long-term growth may be driven by clinical proof-of-concept, partnerships to enable combinations with approved immunotherapies, and expansion of a platform-enabled oncology pipeline that could address safety limits of systemic cytokines.
Principal risks are early-stage clinical and technical uncertainty, limited human data, likely need for additional financing, regulatory approval risk, and strong competition in immuno-oncology.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.99
Dividend Yield
-
Revenue TTM
21.00M
Revenue Per Share
0.44
Gross Profit TTM
-5.18M
Debt / Equity
0.38
ROE
-119.86%
Net Debt
-48.52M
ROCE
-167.07%
Diluted EPS TTM
-0.74

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -60.82M -70.52M -37.37M -53.81M -49.98M
Net income -60.82M -70.52M -37.37M -51.56M -49.77M
Selling general administrative 15.85M 19.05M 18.67M 18.70M 14.82M
Selling and marketing expenses - - 1.76M - -
Gross profit -1.63M 0.07M 18.18M 16.40M -
Reconciled depreciation 1.63M 1.81M 1.72M 1.10M 0.22M
Ebit -55.55M -65.86M -34.23M -57.16M -50.30M
Ebitda -53.91M -64.05M -32.47M -56.06M -50.09M
Depreciation and amortization 1.63M 1.81M 1.76M 1.10M 0.22M
Non operating income net other - - - 2.25M 0.10M
Operating income -60.68M -73.59M -40.50M -56.06M -50.09M
Other operating expenses 60.68M 75.48M 60.45M 72.46M 50.09M
Interest expense 5.27M 4.66M 3.14M 1.10M 0.22M
Interest income 3.11M 6.67M 4.49M 1.91M 0.10M
Net interest income -2.17M 2.02M 4.49M 1.91M 0.10M
Income tax expense - - 1.60M -2.25M -0.22M
Total revenue 0.00M 1.89M 19.94M 16.40M 0.00M
Total operating expenses 59.04M 73.67M 58.68M 72.46M 50.09M
Cost of revenue 1.63M 1.81M 1.76M - -
Total other income expense net -0.14M 3.08M 3.13M 2.25M 0.10M
Net income from continuing ops -60.82M -70.52M -37.30M -53.81M -49.98M
Net income applicable to common shares - - - -53.81M 101.96M
Preferred stock and other adjustments - - - - 151.94M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 69.40M 126.93M 174.83M 160.25M 179.25M
Other current assets 0.64M 2.07M 2.68M 3.96M 3.54M
Total liab 44.59M 53.54M 63.46M 37.91M 26.46M
Total stockholder equity 24.80M 73.39M 111.37M 122.34M 152.79M
Other current liab 33.64M 10.59M 8.86M 14.15M 8.77M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -475.41M -414.59M -344.07M -306.70M -252.90M
Other assets - - 0.00M 10.88M 1.86M
Cash 57.95M 111.00M 134.34M 129.31M 157.53M
Total current liabilities 36.15M 15.18M 19.38M 23.99M 11.87M
Current deferred revenue - - 0.91M 6.53M -
Net debt -48.52M -73.91M -82.42M -114.63M -141.87M
Short term debt 1.75M 1.56M 8.28M 2.08M 1.07M
Short long term debt 28.24M - 6.67M - -
Short long term debt total 9.44M 37.09M 51.92M 14.68M 15.66M
Other stockholder equity 500.21M 487.97M 455.44M 429.04M 405.68M
Property plant equipment - - - 8.99M 16.32M
Total current assets 58.59M 113.07M 138.37M 140.20M 161.07M
Net tangible assets - - - 122.34M 152.79M
Net receivables - - 1.35M 6.93M -
Long term debt - 26.09M 32.66M - -
Accounts payable 0.75M 3.04M 1.34M 1.22M 2.04M
Accumulated other comprehensive income - - - - -179.25M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -306.70M -252.90M
Non currrent assets other 0.01M 1.54M 0.59M 2.59M 1.86M
Non current assets total 10.81M 13.86M 36.46M 20.05M 18.18M
Capital lease obligations 9.44M 10.99M 12.60M 14.68M 15.66M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.25M -1.09M -3.61M -0.50M
Change to liabilities - - - 3.05M 1.01M
Total cashflows from investing activities - -0.25M -0.77M -3.61M -0.50M
Net borrowings 0.00M -10.00M 40.00M -0.09M -
Total cash from financing activities 6.03M 13.08M 58.43M 15.91M 109.43M
Change to operating activities - - - - 1.27M
Net income -60.82M -70.52M -37.37M -53.81M -49.98M
Change in cash -54.26M -43.36M 25.05M -28.30M 66.05M
Begin period cash flow 112.22M 155.58M 130.53M 158.83M 92.78M
End period cash flow 57.95M 112.22M 155.58M 130.53M 158.83M
Total cash from operating activities -60.29M -56.19M -32.61M -40.60M -42.88M
Issuance of capital stock 5.94M 23.58M 10.88M 16.19M 111.60M
Depreciation 1.63M 1.81M 1.76M 1.10M 0.22M
Change to account receivables - 1.35M 5.58M - -
Sale purchase of stock - - - 15.99M 109.43M
Other cashflows from financing activities 6.03M -0.50M 0.10M -0.28M -2.17M
Change to netincome - - - 7.41M 4.61M
Capital expenditures 0.00M 0.25M 0.77M 3.61M 0.50M
Change receivables - - - -6.93M -
Cash flows other operating - - - 8.38M -3.44M
Cash and cash equivalents changes - - - -28.30M 66.05M
Change in working capital -8.21M 2.53M -5.89M 2.54M 2.28M
Stock based compensation 6.25M 8.83M 8.01M 7.40M 4.09M
Other non cash items 0.86M 1.16M 0.88M 2.17M 0.52M
Free cash flow -60.29M -56.44M -33.38M -44.21M -43.37M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HOWL
Werewolf Therapeutics Inc		 0.01
0.74%		 1.00 - - 2.27 2.86 1.17 0.57
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Werewolf Therapeutics Inc

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

200 Talcott Ave, Watertown, MA, United States, 02472

617 952 0555

https://werewolftx.com

39

Name Title Year Born
Dr. Daniel J. Hicklin Ph.D. Founder, CEO, Pres, Sec. & Director 1964
Mr. Timothy W. Trost CPA CFO, Treasurer & Assistant Sec. 1958
Dr. Chulani Karunatilake Ph.D. Chief Technology Officer NA
Dr. Reid Leonard Ph.D. Chief Operating Officer 1959
Dr. Cynthia Seidel-Dugan Ph.D. Chief Scientific Officer 1959
Dr. Randi Isaacs M.D. Chief Medical Officer 1956
Ms. Ellen A. Lubman M.B.A. Chief Bus. Officer 1976
Dr. Daniel J. Hicklin Ph.D. Founder, CEO, President, Secretary & Director 1964
Mr. Timothy W. Trost CPA CFO, Treasurer & Assistant Secretary 1958
Dr. Chulani Karunatilake Ph.D. Chief Technology Officer 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…